Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers

  • Janie M. Lee
  • , Pamela M. McMahon
  • , Chung Y. Kong
  • , Daniel B. Kopans
  • , Paula D. Ryan
  • , Elissa M. Ozanne
  • , Elkan F. Halpern
  • , G. Scott Gazelle

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

Purpose: To evaluate the clinical effectiveness and cost-effectiveness of screening strategies in which MR imaging and screen-film mammography were used, alone and in combination, in women with BRCA1 mutations. Materials and Methods: Because this study did not involve primary data collection from individual patients, institutional review board approval was not needed. By using a simulation model, we compared three annual screening strategies for a cohort of 25-year-old BRCA1 mutation carriers, as follows: (a) screen-film mammography, (b) MR imaging, and (c) combined MR imaging and screen-film mammography (combined screening). The model was used to estimate quality-adjusted life-years (QALYs) and lifetime costs. Incremental cost-effectiveness ratios were calculated. Input parameters were obtained from the medical literature, existing databases, and calibration. Costs (2007 U.S. dollars) and quality-of-life adjustments were derived from Medicare reimbursement rates and the medical literature. Sensitivity analysis was performed to evaluate the effect of uncertainty in parameter estimates on model results. Results: In the base-case analysis, annual combined screening was most effective (44.62 QALYs), and had the highest cost ($110 973), followed by annual MR imaging alone (44.50 QALYs, $108 641), and annual mammography alone (44.46 QALYs, $100 336). Adding annual MR imaging to annual mammographic screening cost $69 125 for each additional QALY gained. Sensitivity analysis indicated that, when the screening MR imaging cost increased to $960 (base case, $577), or breast cancer risk by age 70 years decreased below 58% (base case, 65%), or the sensitivity of combined screening decreased below 76% (base case, 94%), the cost of adding MR imaging to mammography exceeded $100 000 per QALY. Conclusion: Annual combined screening provides the greatest life expectancy and is likely cost-effective when the value placed on gaining an additional QALY is in the range of $50 000-$100 000.

Original languageEnglish
Pages (from-to)793-800
Number of pages8
JournalRadiology
Volume254
Issue number3
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers'. Together they form a unique fingerprint.

Cite this